Using the drop-down menu below, read about highlighted scientific news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2013 ASCO Annual Meeting was held May 31-June 4, with research news released starting May 15. The 2014 event will be held May 30-June 3.
To read these summaries categorized into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting.
Don’t forget to check out audio podcasts and videos about this news, as well. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO's website.
Recent research shows that patients with follicular lymphoma who received the drug rituximab (Rituxan) for two years as maintenance therapy were less likely to have a recurrence (return of cancer after treatment). Maintenance therapy is longer-term treatment given after initial treatment to keep the cancer from returning.
Cancer survivors who participated in a yoga program slept better, had less fatigue, and were less likely to need medication for sleeping problems and fatigue than survivors who did not participate in yoga. Sleeping problems and fatigue are the most common side effects of cancer treatment. In fact, most patients report that they have sleep problems during treatment, and more than half continue to have problems after treatment ends.
A new study showed that patients who received moisturizers, sunscreen, topical steroids, and antibiotics before treatment with panitumumab (Vectibix) were less likely to have a rash from treatment than patients who did not receive the skin treatments until the rash developed. About 90% of people taking panitumumab and 75% of those taking a related drug called cetuximab (Erbitux) develop this rash.
Researchers found that a vaccine called BiovaxID delayed the return of a type of B-cell lymphoma, called follicular lymphoma, by about 14 months for patients whose lymphoma was in remission (the temporary or permanent absence of disease) after treatment with prednisone (multiple brand names), doxorubicin (Adriamycin), cyclophosphamide (Cytoxan, Clafen, Neosar), and etoposide (VePesid, Toposar) - a combination called PACE. The BiovaxID vaccine is made for each patient using proteins that are found on the person's lymphoma cells. It is made from the cells collected during removal of the lymph nodes (tiny, bean-shaped organs that help fight infection). These cells are then processed to create antibodies, which are substances made by the body to help fight infection. These antibodies are designed to kill the patient's own lymphoma cells and are returned to the patient in the form of a vaccine.